Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 07h00 HE
|
Synlogic, Inc.
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
07 nov. 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
01 nov. 2023 14h55 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Synlogic to Participate in Chardan’s Genetic Medicines Conference
21 sept. 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
27 juil. 2023 16h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
24 mai 2023 07h00 HE
|
Jnana Therapeutics, Inc.
Achievement of research milestone for immune program triggers milestone payment BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its...
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
13 févr. 2023 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
20 oct. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
06 sept. 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
Abrupt global expansion of the monkey pox virus has increased the demand for Monkey pox Disease Diagnostics Market - By PMI
25 août 2022 08h53 HE
|
PMI
Covina, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The virus that causes smallpox and the monkeypox both belong to the same family of viruses. Two outbreaks of a disease resembling the pox in groups of...